Modality
Peptide
MOA
IL-13i
Target
Menin
Pathway
PD-1/PD-L1
EoEMCLFSGS
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
May 2018
→ May 2029
Phase 1Current
NCT03925704
2,296 pts·EoE
2018-05→2029-05·Active
NCT03328321
2,778 pts·FSGS
2020-03→2026-07·Recruiting
5,074 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-254mo awayInterim· FSGS
2029-05-143.1y awayInterim· EoE
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P1
Active
P1
Recruit…
Catalysts
Interim
2026-07-25 · 4mo away
FSGS
Interim
2029-05-14 · 3.1y away
EoE
RecruitingActive|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin |